 The Sage Group Strengthens US and EU Team with New Appointment of Mr. Glenn Kazo and Dr. Catherine Beech as Senior Directors
Date: 25 May 2009Cambridge UK and Bridgewater USA – May 2009 – The Sage Group is pleased to announce the appointment of two new Senior Directors – Mr. Glenn Kazo in the USA and Dr. Catherine Beech in the UK/EU. Mr. Kazo and Dr. Beech bring a breadth of additional experience and contacts in the healthcare and life science industry and financial sectors to Sage.
“We are very pleased that Glenn and Catherine have joined Sage as Senior Directors. They will significantly expand our capability and expertise in serving the strategic transactional needs of our clients” said Dr. Bill Mason, an Executive Director of Sage. “Their outstanding track record as life science entrepreneurs and their strong industry backgrounds will bring a strong new dimension to the services we provide our clients, and will assist in the value creation process that Sage brings to all of our clients.”
Mr. Glenn Kazo received his B.Sc. and M.Sc. in Biochemistry from Rutgers University. He has over 25 years of experience in the biopharmaceutical sector as a senior executive and scientist, with extensive business development, strategic planning, corporate financing and marketing experience in the global healthcare arena. In addition to his operational experience, Mr. Kazo has been responsible for raising over $250 million in capital from international investors, including leading efforts in three successful IPOs. Mr. Kazo was a Founder of Enzon Inc., the pioneering drug delivery company that created PEGylation technology. From the many collaborations originated at Enzon, the PEGylation business now includes a growing number of companies with dozens of products in development. Seven PEGylated products currently are on the market that have collectively generated over $25 billion in sales. Subsequently, Mr. Kazo joined Focal, Inc. (now part of Genzyme Corporation) as Vice President Corporate Development, and helped take this biomaterials company public on NASDAQ. He has served on the Board of Directors of XTL, Prolong Pharmaceuticals, a development stage biogeneric company, and iviGene corporation, now a unit of Oragenics, Inc. He was the founding Chair of the Biotechnology Industry Organization (BIO) Strategic Development Committee, and has been active in the Licensing Executives Society, Health Care Manufacturers Association, Association of University Technology Managers, and the Pharmaceutical Research and Manufacturers Association.
Dr Catherine Beech M.B., Ch.B. OBE is medically qualified, with degrees from University of Birmingham (UK) Medical School. She has a strong background in early stage venture capital, with multinational pharmaceutical industry experience both in Europe and the USA. She has expertise in founding, growing and exiting biotechnology and life science businesses. Catherine was awarded the Order of the British Empire (OBE) in the Queen’s Birthday Honors in June 2008 for services to innovation and technology. She is a Member of the UK Society of Investment Professionals. Catherine has previously worked as Director for Medical Affairs UK for Farmitalia Carlo Erba and Senior Director Medical Affairs, Europe, for DuPont Pharmaceuticals. Subsequent to this, she was a Founder of the Cambridge Gateway Fund, a UK-based venture capital fund where she led the healthcare team in a number of investments and was an investment adviser approved by the UK Financial Services Authority. She has sat on numerous Boards of early stage healthcare companies. More recently, she was Chief Executive of Aitua, a private investment company specializing in the commercialization of intellectual property in the life science sector. She has also served as a Member of the UK Department of Trade and Industry’s Technology Strategy Board.
About The Sage Group, Inc.
The Sage Group Inc. is a leader in the provision of strategic and transactional advice to health care companies in the pharmaceutical, diagnostics, medical device, biotechnology and life science fields. Sage currently maintains offices in Branchburg, NJ; Cambridge, England; and Yokohama, Japan. Since its founding in 1994, The Sage Group has served more than 200 clients in the US, Europe and Asia, and completed numerous transactions including divestitures, alliances, acquisitions and financings with values ranging from $5 million to $500 million. The establishment of operations in Europe and Japan over recent years allows its clients to reach out beyond their own regions and capture the potential of the global healthcare market.
The Sage Group is an organization of experienced and successful executives who are committed to the service of the very vital and dynamic health care industry and its investors.
The range of services we provide include:
• Strategic alliances and licensing/partnering
• M&A, divestment, buy- and sell- side
• Global product and technology acquisition searches
• Strategic assessment and planning
• Due diligence, technology and molecule assessment, valuation
• New ventures, interim management
• Facilitating investment in R&D and/or company equity through introductions, network and brokering
The Sage Group's Principals, each an Executive Director, have been Founders, Chairmen, Presidents, CEO's and COO's of a number of emerging health care companies. These Principals have also held senior level management positions in large multi-national organizations. In addition to their management backgrounds, The Sage Group's Principals also have extensive experience in providing professional management consulting services to healthcare industry clients. All these experiences are being applied by The Sage Group to assist industry participants in these challenging times.
The Sage Group can be contacted at any of the offices shown below:
The Sage Group Inc.
1802 Route 31 North, #381
Clinton, NJ 08809
USA
Attn: Wayne Pambianchi
Phone: +1 908-231-9644
Fax: +1 908-231-9692
Email: wp@sagehealthcare.com
Sage Healthcare Ltd.
Church Street Barns
Great Shelford
Cambridge CB22 5EL
United Kingdom
Attn: Dr. Bill Mason
Phone: +44 (0) 1223 844128
Fax: +44 (0) 1223 847871
Email: wtm@sagehealthcare.com
Corporate Website:
http://www.sagehealthcare.com
Sage Japan Inc.
3-5-9 Shimoda-cho
Kohoku-ku, Yokohama
223-0064 Japan
Attn: Yoshihiro Mizuta
Phone: +81-45-561-3717
Fax: +81-45-561-3743
Mobile: +81-90-6011-0003
Email: ym@sagehealthcare.com
|